Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06068153

AMG510 (Sotorasib) Plus Lenvatinib as Second-line Treatment in Patients With KRASG12C Mutant, Metastatic NSCLC — AMBER  

Metastatic Non Small Cell Lung Cancer Clinical Trial

Official title:
A Multicentre, Single-arm Phase II Trial of Sotorasib Plus Lenvatinib, as Second-line Treatment in Patients With KRASG12C-mutant, Metastatic NSCLC

Clinical Trial Summary

AMBER is a multicentre, single-arm phase II trial. The protocol treatment consists of of sotorasib plus lenvatinib, as a second-line treatment. The primary objective of the trial is to evaluate the clinical efficacy of sotorasib plus lenvatinib, in terms of objective response rate, for patients with KRASG12C-mutant, metastatic NSCLC.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06068153
Study type Interventional
Source ETOP IBCSG Partners Foundation
Contact
Status Withdrawn
Phase Phase 2
Start date March 31, 2024
Completion date December 30, 2026
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04965090 - A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC) Phase 2
Recruiting NCT06060613 - Safety and Efficacy of OBX-115 in Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT04884282 - Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) Phase 2
Recruiting NCT05236608 - A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC Phase 1/Phase 2
Recruiting NCT04614103 - Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer Phase 2
Not yet recruiting NCT06066138 - A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing Phase 1
Recruiting NCT05215340 - Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations Phase 3
Recruiting NCT05429320 - A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC) Phase 2
Recruiting NCT05478538 - Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform
Completed NCT01773109 - Etirinotecan Pegol (NKTR-102) in NSCLC Phase 2
Recruiting NCT04743505 - Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) Phase 1/Phase 2
Recruiting NCT05111197 - Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy Phase 3
Recruiting NCT05555732 - Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) Phase 3
Recruiting NCT05676749 - C-TIL051 in Non-Small Cell Lung Cancer Phase 1
Not yet recruiting NCT05566223 - CISH Inactivated TILs in the Treatment of NSCLC Phase 1/Phase 2
Terminated NCT01060514 - Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer Phase 1
Completed NCT05167500 - Efficacy & Safety Study of Lorlatinib in ALK/ROS1 Metastatic NSCLC Patients With Compassionate Use Treatment
Recruiting NCT05259319 - Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT) Phase 1
Enrolling by invitation NCT04697446 - External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC
Completed NCT04511533 - Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations Phase 4